Free Trial
ASX:HLS

Healius (HLS) Stock Price, News & Analysis

Healius logo

About Healius Stock (ASX:HLS)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.33 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
4.46%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Receive HLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Healius and its competitors with MarketBeat's FREE daily newsletter.

HLS Stock News Headlines

Healius Limited Announces Board Changes
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Healius Limited Director Increases Shareholding
See More Headlines

HLS Stock Analysis - Frequently Asked Questions

Healius Limited (ASX:HLS) released its quarterly earnings results on Friday, February, 15th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.09 by $0.06. Healius had a negative net margin of 36.98% and a negative trailing twelve-month return on equity of 49.94%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Healius investors own include bluebird bio (BLUE), Argonaut Gold (AR), Athene (ATH), BELLUS Health (BLU), Esperion Therapeutics (ESPR), Fortress Biotech (FBIO) and Forte Biosciences (FBRX).

Company Calendar

Last Earnings
2/15/2019
Today
12/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
10,500
Year Founded
N/A

Profitability

Net Income
$-636,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.75 billion
Book Value
A$1.43 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.73
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (ASX:HLS) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners